Treatment of pulmonary arterial hypertension;Traitement de l'hypertension artérielle pulmonaire

Presse Medicale

Volumn 34, Issue 19 II, 2005, Pages 1445-1455

  Montani, D ^a   Sitbon, O ^a   Jais X ^a   Cabrol, S ^a   Simonneau, G ^a   Humbert, Marc ^a,b  

^a UNIVERSITÉ PARIS SACLAY   (France)

^b HÔPITAL ANTOINE BÉCLÈRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADRENOMEDULLIN; AMBRISENTAN; AMLODIPINE; ANTICOAGULANT AGENT; BERAPROST; BOSENTAN; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN RECEPTOR ANTAGONIST; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ILOPROST; NIFEDIPINE; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; PROSTACYCLIN; PROSTACYCLIN DERIVATIVE; SILDENAFIL; SIMVASTATIN; SITAXSENTAN; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE; VASODILATOR AGENT; WARFARIN;

ARTERY RESISTANCE; HEART FAILURE; HUMAN; PULMONARY ARTERY; PULMONARY HYPERTENSION; REVIEW; THROMBOSIS; VASOCONSTRICTION;

EID: 27744607667     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84206-x     Document Type: Review

References (72)

1. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary arterial hypertension. N Engl J Med 2004; 351: 1425-36.
2. Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002; 20: 1037-49.
3. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996; 334: 296-302.
4. McLaughlin VV, Shillington A, Rich S. Survival in primary pulmonary hypertension: the impact of epoprostenol therapy. Circulation 2002; 106: 1477-82.
5. Rubin U, Badesch DB, Barst RJ, Galie N, Black CM, Keogh A et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002; 346: 896-903.
6. Bjornsson J, Edwards WD. Primary pulmonary hypertension: a histopathologic study of 80 cases. Mayo Clin Proc 1985; 60: 16-25.
7. Miyamoto S, Nagaya N, Satoh T, Kyotani S, Sakamaki F, Fujita M et al. Clinical correlates and prognostic significance of six-minute walk test in patients with primary pulmonary hypertension. Comparison with cardiopulmonary exercise testing. Am J Respir Crit Care Med 2000; 161: 487-92.
8. Sitbon O, Humbert M, Nunes H, Parent F, Garcia G, Herve P et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. J Am Coll Cardiol 2002; 40: 780-8.
9. Rubin LJ. Primary pulmonary hypertension. N Engl J Med 1997; 336: 111-17.
10. Palevsky HI, Schloo BL, Pietra GG, Weber KT, Janicki JS, Rubin E et al. Primary pulmonary hypertension. Vascular structure, morphometry, and responsiveness to vasodilator agents. Circulation 1989; 80: 1207-21.
11. Fuster V, Steele PM, Edwards WD, Gersh BJ, McGoon MD, Frye RL. Primary pulmonary hypertension: natural history and the importance of thrombosis. Circulation 1984; 70: 580-7.
12. Rich S, Kaufmann E, Levy PS. The effect of high doses of calcium-channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992; 327: 76-81.
13. Rich S, Seidlitz M, Dodin E, Osimani D, Judd D, Genthner D et al. The short-term effects of digoxin in patients with right ventricular dysfunction from pulmonary hypertension. Chest 1998; 114: 787-92.
14. Humbert M, Nunes H, Sitbon O, Parent F, Hervé P, Simonneau G. Risk factors for pulmonary arterial hypertension. Clin Chest Med 2001; 22: 459-75.
15. Rubin LJ. Therapy of pulmonary hypertension: the evolution from vasodilators to antiproliferative agents. Am J Respir Crit Care Med 2002; 166: 1308-9.
16. Sitbon O, Humbert M, Jagot J, Taravella O, Fartoukh M, Parent F et al. Inhaled nitric oxide as a screening agent for safely identifying responders to oral calcium-channel blockers in primary pulmonary hypertension. Eur Respir J 1998; 12: 265-70.
17. Sitbon O, Humbert M, Jais X, Ioos V, Hamid AM, Provencher S et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation 2005; 111: 3105-11.
18. Moncada S, Gryglewski R, Bunting S, Vane JR. An enzyme isolated from arteries transforms prostaglandin endoperoxides to an unstable substance that inhibits platelet aggregation. Nature 1976; 263: 663-5.
19. Rubin LJ, Mendoza J, Hood M, McGoon M, Barst R, Williams WB et al. Treatment of primary pulmonary hypertension with continuous intravenous prostacyclin (epoprostenol). Results of a randomized trial. Ann Intern Med 1990; 112: 485-91.
20. Castelain V, Chemla D, Humbert M, Sitbon O, Simonneau G, Lecarpentier Y et al. Pulmonary artery pressure-flow relations after prostacyclin in primary pulmonary hypertension. Am J Respir Crit Care Med 2002; 165: 338-40.
21. Higenbottam T, Wheeldon D, Wells F, Wallwork J. Long-term treatment of primary pulmonary hypertension with continuous intravenous epoprostenol (prostacyclin). Lancet 1984; 1: 1046-7.
22. Shapiro SM, Oudiz RJ, Cao T, Romano MA, Beckmann XJ, Georgiou D et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol 1997; 30: 343-9.
23. Robbins IM, Christman BW, Newman JH, Matlock R, Loyd JE. A survey of diagnostic practices and the use of epoprostenol in patients with primary pulmonary hypertension. Chest 1998; 114: 1269-75.
24. Humbert M, Maitre S, Capron F, Rain B, Musset D, Simonneau G. Pulmonary edema complicating continuous intravenous prostacyclin in pulmonary capillary hemangiomatosis. Am J Respir Crit Care Med 1998; 157: 1681-5.
25. Badesch DB, Tapson VF, McGoon MD, Brundage BH, Rubin LJ, Wigley FM et al. Continuous intravenous epoprostenol for pulmonary hypertension due to the scleroderma spectrum of disease. A randomized, controlled trial. Ann Intern Med 2000; 132: 425-34.
26. Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999; 99: 1858-65.
27. Kuo PC, Johnson LB, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous intravenous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997; 63: 604-6.
28. Aguilar RV, Farber HW. Epoprostenol (prostacyclin) therapy in HIV-associated pulmonary hypertension. Am J Respir Crit Care Med 2000; 162: 1846-50.
29. Nunes H, Humbert M, Sitbon O, Morse JH, Deng Z, Knowles JA et al. Prognostic factors for survival in human immunodeficiency virus-associated pulmonary arterial hypertension. Am J Respir Crit Care Med 2003; 167: 1433-9.
30. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-70.
31. Gessler T, Schmehl T, Hoeper MM, Rose F, Ghofrani HA, Olschewski H et al. Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension. Eur Respir J 2001; 17: 14-19.
32. Olschewski H, Simonneau G, Galie N, Higenbottam T, Naeije R, Rubin LJ et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med 2002; 347: 322-9.
33. Simonneau G, Barst RJ, Galie N, Naeije R, Rich S, Bourge RC et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002; 165: 800-4.
34. Vachiery JL, Hill N, Zwicke D, Barst R, Blackburn S, Naeije R. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Chest 2002; 121: 1561-5.
35. Okano Y, Yoshioka T, Shimouchi A, Satoh T, Kunieda T. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997; 349: 1365.
36. Barst RJ, McGoon M, McLaughlin V, Tapson V, Rich S, Rubin L et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-25.
37. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988; 332: 411-15.
38. DiCarlo VS, Chen SJ, Meng QC, Durand J, Yano M, Chen YF et al. ETA-receptor antagonist prevents and reverses chronic hypoxia-induced pulmonary hypertension in rat. Am J Physiol 1995; 269: L690-7.
39. Hirata Y, Takagi Y, Fukuda Y, Marumo F. Endothelin is a potent mitogen for rat vascular smooth muscle cells. Atherosclerosis 1989; 78: 225-8.
40. Channick RN, Simonneau G, Sitbon O, Robbins IM, Frost A, Tapson VF et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001; 358: 1119-23.
41. Galie N, Hinderliter AL, Torbicki A, Fourme T, Simonneau G, Pulido T et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 1380-6.
42. McLaughlin VV, Sitbon O, Badesch DB, Barst RJ, Black C, Galie N et al. Survival with first-line bosentan in patients with primary pulmonary hypertension. Eur Respir J 2005; 25: 244-9.
43. Sitbon O, Badesch DB, Channick RN, Frost A, Robbins IM, Simonneau G et al. Effects of the dual endothelin receptor antagonist bosentan in patients with pulmonary arterial hypertension: a 1-year follow-up study. Chest 2003; 124: 247-54.
44. Sitbon O, McLaughlin VV, Badesch D, Barst RJ, Black C, Galie N et al. Survival in patients with class III idiopathic pulmonary arterial hypertension treated with first-line oral bosentan compared with an historical cohort of patients started on i.v. epoprostenol. Thorax 2005 (sous presse).
45. Barst RJ, Rich S, Widlitz A, Horn EM, McLaughlin V, McFarlin J. Clinical efficacy of sitaxsentan, an endothelin-A receptor antagonist, in patients with pulmonary arterial hypertension: open-label pilot study. Chest 2002; 121: 1860-8.
46. Galie N, Badesch D, Oudiz R, Simonneau G, McGoon M, Keogh A et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 529-35.
47. Ghofrani HA, Wiedemann R, Rose F, Schermuly RT, Olschewski H, Weissmann N et al. Sildenafil for treatment of lung fibrosis and pulmonary hypertension: a randomised controlled trial. Lancet 2002; 360: 895-900.
48. Prasad S, Wilkinson J, Gatzoulis MA. Sildenafil in primary pulmonary hypertension. N Engl J Med 2000; 343: 1342.
49. Rubin L, Burgess G, Parpia T, Simonneau G. Effects of sildenafil on 6-minute walk distance and WHO functional class after 1 year of treatment. Proc Am Thorac Soc 2005; 2: A299.
50. Herve P, Launay JM, Scrobohaci ML, Brenot F, Simonneau G, Petitpretz P et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995; 99: 249-54.
51. Marcos E, Adnot S, Pham MH, Nosjean A, Raffestin B, Hamon M et al. Serotonin transporter inhibitors protect against hypoxic pulmonary hypertension. Am J Respir Crit Care Med 2003; 168: 487-93.
52. Nishimura T, Faul JL, Berry GJ, Vaszar LT, Qiu D, Pearl RG et al. Simvastatin attenuates smooth muscle neointimal proliferation and pulmonary hypertension in rats. Am J Respir Crit Care Med 2002; 166: 1403-8.
53. Girgis RE, Li D, Zhan X, Garcia JG, Tuder RM, Hassoun PM et al. Attenuation of chronic hypoxic pulmonary hypertension by simvastatin. Am J Physiol Heart Circ Physiol 2003; 285: H938-45.
54. Nishimura T, Vaszar LT, Faul JL, Zhao G, Berry GJ, Shi L et al. Simvastatin rescues rats from fatal pulmonary hypertension by inducing apoptosis of neointimal smooth muscle cells. Circulation 2003; 108: 1640-5.
55. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003; 111: 1339-46.
56. Nagaya N, Kyotani S, Uematsu M, Ueno K, Oya H, Nakanishi N et al. Effects of adrenomedullin inhalation on hemodynamics and exercise capacity in patients with idiopathic pulmonary arterial hypertension. Circulation 2004; 109: 351-6.
57. Upton PD, Wharton J, Coppock H, Davie N, Yang X, Yacoub MH et al. Adrenomedullin expression and growth inhibitory effects in distinct pulmonary artery smooth muscle cell subpopulations. Am J Respir Cell Mol Biol 2001; 24: 170-8.
58. Nagaya N, Miyatake K, Kyotani S, Nishikimi T, Nakanishi N, Kangawa K. Pulmonary vasodilator response to adrenomedullin in patients with pulmonary hypertension. Hypertens Res 2003; 26 Suppl: 141-6.
59. Kandler MA, Von Der Hardt K, Mahfoud S, Chada M, Schoof E, Papadopoulos T et al. Pilot intervention: aerosolized adrenomedullin reduces pulmonary hypertension. J Pharmacol Exp Ther 2003; 306: 1021-6.
60. Humbert M, Barst RJ, Robbins IM, Channick RN, Galie N, Boonstra A et al. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2. Eur Respir J 2004; 24: 353-9.
61. Bigatello LM, Hess D, Dennehy KC, Medoff BD, Hurford WE. Sildenafil can increase the response to inhaled nitric oxide. Anesthesiology 2000; 92: 1827-9.
62. Ghofrani HA, Wiedemann R, Rose F, Olschewski H, Schermuly RT, Weissmann N et al. Combination therapy with oral sildenafil and inhaled iloprost for severe pulmonary hypertension. Ann Intern Med 2002; 136: 515-22.
63. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-4.
64. Ghofrani HA, Rose F, Schermuly RT, Olschewski H, Wiedemann R, Kreckel A et al. Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension. J Am Coll Cardiol 2003; 42: 158-4.
65. Kerstein D, Levy PS, Hsu DT, Hordof AJ, Gersony WM, Barst RJ. Blade balloon atrial septostomy in patients with severe primary pulmonary hypertension. Circulation 1995; 91: 2028-35.
66. Sandoval J, Gaspar J, Pulido T, Bautista E, Martinez-Guerra ML, Zeballos M et al. Graded balloon dilation atrial septostomy in severe primary pulmonary hypertension. A therapeutic alternative for patients nonresponsive to vasodilator treatment. J Am Coll Cardiol 1998; 32: 297-304.
67. Rothman A, Sklansky MS, Lucas VW, Kashani IA, Shaughnessy RD, Channick RN et al. Atrial septostomy as a bridge to lung transplantation in patients with severe pulmonary hypertension. Am J Cardiol 1999; 84: 682-6.
68. Levine SM, Gibbons WJ, Bryan CL, Walling AD, Brown RW, Bailey SR et al. Single lung transplantation for primary pulmonary hypertension. Chest 1990; 98: 1107-15.
69. Pielsticker EJ, Martinez FJ, Rubenfire M. Lung and heart-lung transplant practice patterns in pulmonary hypertension centers. J Heart Lung Transplant 2001; 20: 1297-304.
70. Mendeloff EN, Meyers BF, Sundt TM, Guthrie TJ, Sweet SC, de la Morena M, Shapiro S et al. Lung transplantation for pulmonary vascular disease. Ann Thorac Surg 2002; 73: 209-217.
71. Reitz BA, Wallwork JL, Hunt SA, Pennock JL, Billingham ME, Oyer PE et al. Heart-lung transplantation: successful therapy for patients with pulmonary vascular disease. N Engl J Med 1982; 306: 557-64.
72. Hosenpud JD, Bennett LE, Keck BM, Boucek MM, Novick RJ. The Registry of the International Society for Heart and Lung Transplantation: eighteenth Official Report-2001. J Heart Lung Transplant 2001; 20: 805-15.